Contractor Notice: SSP010 for Levothyroxine 12.5mcg tablets extended

THIS CONTENT HAS NOW EXPIRED

Contractor Notice: SSP010 for Levothyroxine 12.5mcg tablets extended

March 26, 2021

Update 26th March 2020

The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocols (SSPs) for Levothyroxine 12.5mcg tablets (SSP010).

SSP010 for Levothyroxine 12.5mcg tablets was previously expected to expire on 26th March 2021 but the end date has been further extended to 1st April 2021. Please see further information below


The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocols (SSPs) for Levothyroxine 12.5mcg tablets (SSP010).

SSP010 for Levothyroxine 12.5mcg tablets was previously expected to expire on 19th March 2021 but the end date has been further extended to 26th March 2021.

Please note: expiry dates of an SSP may be brought forward or extended, and the content may be amended at any time during the life of an SSP. Pharmacists should ensure they are using the latest version of an SSP before considering the supply of an alternative product.

Summary

SSP & Product Current expiry date
SSP010: Levothyroxine 12.5mcg tablets This SSP has been varied – the revised end date for SSP010 is now 26th March 2021

Current versions of SSPs can be found at: www.nhsbsa.nhs.uk/pharmacies-gp-practices-andappliance-contractors/serious-shortage-protocols-ssps

The SSP recommendations

SSP10 provides that for every two Levothyroxine 12.5 mcg tablets originally prescribed, one Levothyroxine 25 microgram tablet must be supplied with the dosage amended to one 25mcg tablet to be taken on alternate days as follows:

For prescriptions (NHS or private) requesting: Supply permitted under SSP010:
Levothyroxine 12.5mcg tablets (56 tablets) Levothyroxine 25mcg tablets (28 tablets)

The pharmacist must exercise their professional judgement to ensure the alternative product is suitable for the patient.

Other active SSPs

SSP Expiry Date
SSP005: Fluoxetine 10mg tablets
31st March 2021
SSP007: Fluoxetine 30mg capsules 17th May 2021
SSP009: Fluoxetine 40mg capsules 31st March 2021

Reimbursement and remuneration

Reimbursement is for the medicine supplied in accordance with the SSP and not the originally prescribed medicine. The reimbursement price will account for VAT payment. Supply in accordance with the SSP will result in the following fees being paid to the contractor:

  • One Single Activity fee (currently £1.27)
  • One SSP fee (£5.35)

Support in implementing the SSPs

The following resources have been developed to support pharmacy teams in using these protocols.

Submission of Serious Shortage Protocol (SSP) claims using EPS tokens

PSNC Briefing 004/21: Serious Shortage Protocol (SSP): SSP010 – Levothyroxine 12.5mcg tablets

Current versions of SSPs

Serious Shortage Protocols Operational Guidance

Serious Shortage Protocols Questions & Answers

PSNC’s Serious Shortage Protocols (SSPs) Endorsing Factsheet

PSNC Briefing 023/19: Serious Shortage Protocols – A guide for community pharmacy teams

Background information on SSPs

Further information on what SSPs are and when they may be used is available via the links below.

Serious Shortage Protocols (SSPs) on-demand webinar

Serious Shortage Protocols (SSPs) webpage



Posted in: , ,


More Latest News >